phosphate buffer (pH 8.0) with a Polytron homogenizer. The resulting samples were centrifuged (3,000rpm, 10 minutes) after the addition of DFP and the supernatants thus obtained were kept frozen at -20°C until analyzed. During periods of0 to 24, 24 to 48 hours, urine and feces were collected in metabolic cages. The urine samples were diluted with 1/15 m phosphate buffer (pH 8.0) after the addition of DFP. The feces were homogenized in 10 volumes of the same buffer with a Polytron homogenizer and centrifuged after the addition of DFP.
The bioactivity in the samples was determined by an agar-well method using Micrococcus luteus
ATCC9341 as the test organism, in Trypto Soy
Agar (pH8.0, Eiken, Japan). Standard curves for the drugs were prepared with plasma or tissue homogenates from control mice. The tissue and plasma concentrations of the drugs were determined by bioassay in mice after iv administration at a 20-mg/kg dose and the results are shown in Table 1 . The concentrations of these compounds in plasma were 7.0 to 9.6/jg/ml 5 minutes after administration and werereduced to 0.8 to 2.2 /zg/ml after 1 hour. These compounds were rapidly distributed to all tissues and showed excellent penetration in the lung, liver, spleen and kidney. In the lung, TMC-015 showed the best penetration (AUC: 63.0 /zg -hour/g) among the drugs tested; on the other hand TMC-016 showed a prolonged T1/2 (1.09 hours). Whereas the administration of TMC-015 resulted in the highest antibiotic concentrations in the kidney, 4'-deoxydesmycosin produced the highest level in the liver. However, both derivatives were rapidly eliminated from these organs. The levels in skin were gradually elevated to achieve the maximum concentration (Cmax), and the high levels were long-lasting.
The 19-deformyl derivatives, TMC-014, TMC-015 and TMC-016, were rapidly absorbed when, administered orally and were demonstrated tissue distributions comparable to that following iv administration.
As shown in Table 2 , the Cmaxof TMC-014, TMC-016 and TMC-015 in plasma after administration of 20mg of the drug per kg was 3.2, 2.2 and 2.0/xg/ml, respectively. TMC-014showed the highest levels in almost all tissues and the levels in the lung were 8.5^g/g, indicating excellent
penetration. Although the tissue levels of TMC-015
were rather low, the levels in the lung were exceptionally high, a Cmax of 10.1fig/g and an AUCratio (tissue/plasma) of 1 1.0.
On the other hand, the 19-formyl derivative, 4'-deoxydesmycosin, showed very poor absorption when orally administered. The plasma level 2 hours after administration was only 0.1 jug/ml and the tissue levels were also low even in the liver. The bioavailability (as estimated by po/iv AUC ratios) of TMC-014 and TMC-016 was excellent (105 and 81%, respectively) and that of TMC-015 was rather low (54%). The cumulative excretion data in urine and feces are shown in Table 3 . Over a 48-hour period, 37.0, 21.0 and 49.1% of the iv dose of TMC-014, TMC-015 and TMC-016 was excreted as microbiologically active compound. Similarly, 33.2% of the iv dose of 4'-deoxydesmycosin was excreted. However, 4'-deoxydesmycosin, as well as desmycosin and tylosin5) showed very poor absorption, whereas all the deformyl derivatives were well absorbed and rapidly distributed to all tissues when orally administered. This finding suggests that the greatly increased efficacy of the 19-deformyl compounds3) when administered orally is caused mainly by their increased absorption.
In the studies with iv administration of the drugs, 4'-deoxydesmycosin was rapidly distributed to all tissues, especially the liver; however, its elimination TMC-015 penetrated the kidney and lung in very high concentrations, however, it was excreted rapidly from the kidney. The levels of TMC-015 in the lung were also high when it was administered orally and almost equal to that of clarithromycin, which has been reported to have excellent ability to penetrate the lung.6) However, the bioavailability of TMC-015 was lower than that of TMC-014 and TMC-016.
